The Cure Sickle Cell Initiative: Catalyzing Progress via Innovative Interfaces Between NIH, Patients, Academics, ASH, and the Private Sector
Dr. Edward Benz provides some background on the discovery of sickle cell disease and development of the Cure Sickle Cell Initiative. Dr. Ify Osunkwo adds further perspectiv
A New Standard of Care for Children and Young Adults With T-cell Acute Lymphoblastic Leukemia
Dr. Teachey reviews a study that shows outstanding outcomes for children and young adults with T-cell acute lymphoblastic leukemia that have raised the bar and established
Dr. Abdel-Wahab reviews a study that looks at the use of circulating tumor DNA measurements to predict early outcome in diffuse large B-cell lymphoma and calls for implementation of clinical trials.
Dr. Abdel-Wahab reviews a study that suggests dissemination of bacteria from the gastrointestinal system and ensuing microbial-dependent inflammation may drive the development of myeloid malignancy in subjects with clonal hematopoiesis.
Dr. Abdel-Wahab looks at several studies that show different ways to reactivate wild-type p53 as a therapeutic option in leukemia and other forms of cancer.
Dr. Abdel-Wahab looks at a study that evaluates the efficacy of PD-1 inhibition in myeloproliferative neoplasms, focusing on how JAK2 mutations affect PD-L1 expression.
Dr. Abdel-Wahab takes a look at studies that explore the enzyme METTL3 and RNA methyltransferases as a novel therapy for acute myeloid leukemia.
Dr. Abdel-Wahab reviews the FDA approval in 2017 of four new therapeutic options for treating acute myeloid leukemia patients.
Dr. Abdel-Wahab discusses the use of vitamin C to restore TET2 deficiency in combination with PARP inhibition in the treatment of leukemia.
Dr. Abdel-Wahab and Dr. Taylor look at a study that evaluates the safety of combining the anti-PD-L1 antibody atezolizumab with the novel hypomethylating agent guadecitabine in older adults with AML not eligible for standard induction therapy.
Dr. Abdel-Wahab provides an overview of histiocytoses or histiocytic neoplasms, some of the most challenging hematologic disorders to diagnose and categorize.
Dr. Abdel-Wahab discusses the effects of SAMHD1 depletion on the response to multiple chemotherapeutic agents.
November-December 2018Volume 15, Issue 6
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology